Pfizer stock traded down Tuesday on a "pretty uneventful quarter" as revenue from its Covid products helped drive a fourth-quarter beat. Please watch the video at Investors.com - How To Buy Stocks ...

UBS Group reduced their target price on Pfizer from $31.00 to $29.00 ... distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers ...

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide.

Both of Genzyme's products ... prevalent among the group of lysosomal storage disorders, which have been a historic focus for Genzyme in Cambridge, Massachusetts. This is Pfizer's first move ...

Representative Julie Johnson (D-Texas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 12th, the Representative disclosed that they had sold between $1,001 and $15,000 ...

The past year has been all about delivering the COVID-19 vaccine, but there's strong revenue growth from the rest of Pfizer's lineup as well. Pfizer (PFE) discovers, develops, manufactures ...

Valued at a market cap of $152.2 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company ... company's extensive portfolio encompasses products like Eliquis, Comirnaty, and Paxlovid ...

Angela Hwang is a member of Pfizer’s executive team and the chief commercial officer and president of Pfizer’s global biopharmaceuticals ... medicines and products to patients.

The studies will be overseen by both Summit and Pfizer. Both parties retain their respective rights to their products ... is a leading biopharmaceutical company committed to the research ...

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products ...